Overview

Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer

Status:
Terminated
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of Epalrestat in the treatment of metastatic triple negative breast
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Epalrestat